Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Srinivas

Showing results (51-60 of 935) with videos related to

Pageof 94
Sort By:
Antiviral Therapy|August 24, 2016
Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerationsNuggehally R Srinivas
Future Microbiology|July 8, 2017
Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectivesNuggehally R Srinivas
European Journal of Drug Metabolism and Pharmacokinetics|June 27, 2019
Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese SubjectsNuggehally R Srinivas
European Journal of Clinical Pharmacology|March 23, 2011
PK/PD modeling of rabeprazole in CYP2C19 genotypes: consideration of the influence of thio-ether metabolite, CYP3A4, accumulation and CYP2D6 polymorphism may help to better develop and validate the modelNuggehally R Srinivas
Biomedical Chromatography : BMC|January 1, 1994
A note on chromatographic analysis of enantiomers by indirect methodN R Srinivas
Journal of Clinical Pharmacology|December 4, 2009
Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicinNuggehally R Srinivas
Biomedical Chromatography : BMC|May 1, 1994
A need for a uniform approach for indexing data of the stereoisomersN R Srinivas
Clinical Drug Investigation|September 30, 2015
Phenylephrine Pharmacokinetics and First-Pass Metabolism: What Is an Ideal Pharmacokinetic Surrogate?Nuggehally R Srinivas
Drug Development and Industrial Pharmacy|October 16, 2015
Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolitesNuggehally R Srinivas
Alimentary Pharmacology & Therapeutics|December 8, 2015
Prostaglandin E1 therapy with alprostadil and risk reduction in early hepatic cellular carcinoma after liver transplantationN R Srinivas
Pageof 94

Showing results (51-60 of 935) with videos related to

Sort By:
Pageof 94
Antiviral Therapy|August 24, 2016
Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerationsNuggehally R Srinivas
Future Microbiology|July 8, 2017
Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectivesNuggehally R Srinivas
European Journal of Drug Metabolism and Pharmacokinetics|June 27, 2019
Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese SubjectsNuggehally R Srinivas
European Journal of Clinical Pharmacology|March 23, 2011
PK/PD modeling of rabeprazole in CYP2C19 genotypes: consideration of the influence of thio-ether metabolite, CYP3A4, accumulation and CYP2D6 polymorphism may help to better develop and validate the modelNuggehally R Srinivas
Biomedical Chromatography : BMC|January 1, 1994
A note on chromatographic analysis of enantiomers by indirect methodN R Srinivas
Journal of Clinical Pharmacology|December 4, 2009
Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicinNuggehally R Srinivas
Biomedical Chromatography : BMC|May 1, 1994
A need for a uniform approach for indexing data of the stereoisomersN R Srinivas
Clinical Drug Investigation|September 30, 2015
Phenylephrine Pharmacokinetics and First-Pass Metabolism: What Is an Ideal Pharmacokinetic Surrogate?Nuggehally R Srinivas
Drug Development and Industrial Pharmacy|October 16, 2015
Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolitesNuggehally R Srinivas
Alimentary Pharmacology & Therapeutics|December 8, 2015
Prostaglandin E1 therapy with alprostadil and risk reduction in early hepatic cellular carcinoma after liver transplantationN R Srinivas
Pageof 94